Generated by AI
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on developing immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its primary program centers on GP2, an investigational peptide-based immunotherapy designed to help prevent breast cancer recurrence after surgery. The company’s research and clinical activities are concentrated on advancing cancer vaccines and immune-based treatments that target HER2-related disease, a major area in oncology where precision therapies play an important role. Greenwich LifeSciences operates as a biotechnology developer rather than a commercial drug producer, with its current work centered on clinical evaluation, safety, and efficacy of its lead candidates. Based in Stafford, Texas, Greenwich LifeSciences is positioned within the broader life sciences sector as a specialized company addressing unmet needs in post-treatment breast cancer care.
WebsiteBuilding 14
Stafford, TX, 77477
United States
The latest articles about GLSI.
Analyst rates Greenwich LifeSciences, Inc., a Buy: open-label data showed 70%-80% lower recurrence in 250 non-HLA-A*02 patients, backing Phase 3 expansion.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Summary of Jan 22's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about GLSI also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.